NL-OMON33831已完成2 期
A RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, 5-WAY, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ONO-8539 IN PATIENTS WITH OVERACTIVE BLADDER - Emerald
ONO Pharma0 个研究点目标入组 70 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) medical history of OAB symptoms with urinary urgency for >6 months prior to screening
- •2) during the placebo run-in phase a) >8 micturitions per 24 hrs, and either b) >1 urgency episode per 24 hrs and >6 urgency episode per 72 hrs or c) >1 urinary urgency incontinence episode per 24 hrs (on each day recorded in the 3-day diary period).
排除标准
- •History of lower urinary tract pathology that could be responsible for urgency or incontinence (e.g. genuine stress incontinence, bladder stones, interstitial cystitis, urothelial tumours), neurogenic detrusor overactivity and urinary tract infections.
研究者
相似试验
进行中（未招募）
不适用
A RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, 5-WAY, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ONO-8539 IN PATIENTS WITH OVERACTIVE BLADDEROveractive bladderMedDRA version: 9.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2007-006538-33-SEOno Pharmaceutical Co. Ltd.440
进行中（未招募）
不适用
A RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, 5-WAY, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ONO-8539 IN PATIENTS WITH OVERACTIVE BLADDEREUCTR2007-006538-33-CZOno Pharmaceutical Co. Ltd.440
进行中（未招募）
不适用
A RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, 5-WAY, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ONO-8539 IN PATIENTS WITH OVERACTIVE BLADDEROveractive bladderMedDRA version: 9.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2007-006538-33-NLOno Pharmaceutical Co. Ltd.400
进行中（未招募）
不适用
A RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, 5-WAY, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ONO-8539 IN PATIENTS WITH OVERACTIVE BLADDEREUCTR2007-006538-33-HUOno Pharmaceutical Co. Ltd.440
未知
不适用
A MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFECT OF FOSTAMATINIB 100 MG TWICE DAILY ON 24-HOUR AMBULATORY BLOOD PRESSURE IN PATIENTS WITH RHEUMATOID ARTHRITISPER-054-12AstraZeneca AB,